OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression

Ítems similars

• Immunotherapy expands and maintains the function of high affinity tumor infiltrating CD8 T cells in situ
  per: Moran, Amy E., et al.
  Publicat: (2016)
• Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
  per: Erika J. Crosby, et al.
  Publicat: (2018-05-01)
• Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
  per: Crosby, Erika J., et al.
  Publicat: (2018)
• Finding the right balance: aOX40 immunotherapy enhances effector T cell function without impairing regulatory T cells intrinsic suppressive capacity in mouse tumor models
  per: Moran, Amy, et al.
  Publicat: (2015)
• STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors
  per: Akporiaye, Emmanuel T, et al.
  Publicat: (2013)